Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04207944 · ClinicalTrials.gov registry record · Phase 2
The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)
A Phase 2 study of IPMN, Pancreatic and IPMN, sponsored by Duke University.
- Active
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 4
- Study locations
NCT04207944 is a Phase 2 study of IPMN, Pancreatic and IPMN that is active but no longer recruiting, run by Duke University. The registered enrollment target is 100 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT04207944, a Phase 2 study of IPMN, Pancreatic and IPMN, is active but no longer recruiting, sponsored by Duke University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a multi-center randomized double-blind placebo controlled trial of patients with high-risk intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. The primary objective is to evaluate the effect of sulindac on the presence or absence of progression of IPMN after up to 3 years of treatment. Patients without contraindications will be considered to be eligible and will be required to have a cross-sectional imaging study of the pancreas by CT scan or MRI within 3 months of study entry to document residual IPMNs and to rule out any evidence of pancreatic cancer. Patients will be randomized to receive either sulindac (200 mg p.o. BID) plus standard radiographic and endoscopic surveillance or placebo plus standard radiographic and endoscopic surveillance. Randomization will be stratified by (1) whether the patient had high-grade dysplasia identified in the initial resection specimen (resected patients only) and (2) whether the patient is taking metformin at the time of randomization.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Sulindac 400 MG
Study Locations (4)
Maryland
- Johns Hopkins University - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
New York
- Memorial Sloan Kettering - New York
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2020-07-10 |
| Est. Completion | 2026-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04207944
The ClinicalTrials.gov registry entry for NCT04207944 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with IPMN, Pancreatic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04207944 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Maryland, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT04207944 about?
NCT04207944 is a clinical study titled "The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)". This is a multi-center randomized double-blind placebo controlled trial of patients with high-risk intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. The primary objective is to evaluate the effect of sulindac on the presence or absence of progression of IPMN after up to 3 years of tr...
What is the current status of trial NCT04207944?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2020-07-10. Estimated completion is 2026-10-31.
What conditions does trial NCT04207944 study?
This clinical trial studies the following conditions: IPMN, Pancreatic, IPMN.
What interventions are being tested in trial NCT04207944?
The interventions under investigation include: Placebo (OTHER), Sulindac 400 MG (DRUG).
Who is sponsoring clinical trial NCT04207944?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04207944 being conducted?
This trial has 4 study locations across Maryland, Massachusetts, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for IPMN, Pancreatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.